Radiotherapy cannot prolong overall survival of young prostate cancer patients with bone metastases

Table 2 Univariate analysis for survival

Factors	N	Survival rate (%)						Mean survival (month)	Median survival (month)	P value
Factors	N	1 year	2 years	3 years	5 years	7 years	10 years	Mean survival (month)	Median survival (month)	P value
Radiotherapy on metastasis sites										0.817
With	35	97.14	82.86	62.61	38.76	25.83	13.84	66.1	54
Without	69	92.75	73.91	54.66	36.63	26.03	17.85	59.4	46
Chemotherapy										0.875
With	19	94.74	78.95	68.42	38.6	20.58	20.58	62.3	53
Without	85	94.12	76.47	54.76	36.82	26.48	15.61	65.2	46
Gleason scores when diagnosed as PCa										0.564
2–4	1	100.00	100.00	100.00	100.00	0.00	0.00	79.0	79
5–7	31	100.00	90.32	57.45	42.79	28.53	23.77	75.5	45
8–10	72	91.67	70.83	56.66	33.80	24.96	11.88	55.0	49
PSA when bone metastases occurred										0.692
<4 ng ml⁻¹	7	85.71	71.43	71.43	42.86	28.57	14.29	61.4	54
4–20 ng ml⁻¹	10	90.00	80.00	70.00	45.00	45.00	22.50	78.6	58
>20 ng ml⁻¹	87	95.40	77.01	54.71	35.74	23.36	15.73	58.1	45
ALP when bone metastases occurred										0.020
<150 U I⁻¹	51	96.09	82.35	64.4	45.6	33.74	24.78	78.6	57
≥150 U I⁻¹	53	82.45	71.70	50.8	28.16	15.08	0.00	46.7	40
The number of bone metastases										0.006
Single	18	100	94.44	77.78	66.67	49.38	39.51	104.8	84
Multiple	86	93.02	73.26	53.07	30.46	20.35	10.97	53.1	40
Regional lymph node metastases										0.011
With	21	90.48	57.14	28.57	21.43	21.43	10.71	71.0	54
Without	83	95.18	81.93	64.82	41.60	27.51	17.59	42.9	31
Metastases when bone metastases occurred										0.588
Without	72	98.61	80.56	59.35	38.29	25.54	17.69	69.5	52
Neighbouring organs^a	23	78.26	65.22	51.51	32.78	27.31	–	47.9	43
Distant organs^b	9	100.00	77.78	55.56	41.67	–	–	44.3	53

ALP alkaline phosphatase; PSA prostate-specific antigen
^a Defined as an organ around with prostate, such as the bladder, spermatophores, urethra and rectum
^b Defined as brain, lung and liver metastases

ISSN: 1479-5876